Inozyme Pharma appoints Erik Harris as Class II director effective October 3, 2024

Inozyme Pharma, Inc.

Erik Harris, Chief Commercial Officer and EVP at Ultragenyx, appointed to Inozyme's Board as Class II director.
Director compensation: $40,000 annual cash retainer, initial option for 56,000 shares (3-year vest), annual option for 28,000 shares.
Mr. Harris has over 20 years of biopharma commercial experience including roles at InterMune, Genentech, and Bristol-Myers Squibb.
Standard indemnification agreement entered into; no family relationships or transactions with Inozyme officers require disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erik Harris

Director

Inozyme Pharma, Inc.

Effective: 2024-10-03
Filed: October 7, 2024, 7:59 PM ET

appointed Erik Harris as a director of the Company, effective October 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Harris was appointed as Director at Inozyme Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Erik Harris as a director of the Company, effective October 3, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-113241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.